Drugs / BCG Medac Strain
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06816017 Background | Jun 2025 → Oct 2028 | non-invasive bladder urothelial carcinoma | Hoffmann-La Roche | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCG Medac Strain | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06816017 ↗ |
| Route | Other | “Participants will receive BCG via intravesical instillation.” NCT06816017 ↗ |